{"success":true,"data":{"pressRelease":{"id":"19178","rtpr_id":"nACS1597ha","ticker":"XCRT","exchange":"OTC","all_tickers":["XCRT"],"title":"Xcelerate Announces Agreements with Tanzanian Medical Professionals","author":"ACCESSWIRE","published_at":"2026-05-04T13:24:44.133Z","article_body":"XCELERATE ANNOUNCES AGREEMENTS WITH TANZANIAN MEDICAL PROFESSIONALS TO BEGIN\nLOCAL OPERATIONS\n\nAgreement with Dr. Desire Ruhinda will allow the Company to move forward with\nits pilot program\n\nMAULDIN, SC / ACCESS Newswire (https://www.accessnewswire.com/) / May 4, 2026\n/ Xcelerate Inc. (OTCQB:XCRT) today announced that its majority-owned\nsubsidiary, AfiyaSasa Africa LLC, has entered into a consulting agreement with\nTanzanian medical doctor Dr. Desire Ruhinda to support the next phase of the\nCompany's AfiyaSasa Africa initiative, while also confirming a May on-site R&D\nengagement led by its Chief Science Officer, Dr. Anja Glisovic.\n\nThe agreement with Dr. Ruhinda marks a transition from strategic planning to\noperational execution of the Company's previously announced initiative to\nevaluate artificial intelligence-enabled healthcare delivery models in\nunderserved markets.\n\nUnder the agreement, current efforts will focus on reviewing the capabilities\nof the AdviNOW Medical system, identifying localization requirements, and\ncompiling clinical data aligned with Tanzanian treatment guidelines and\npharmaceutical standards. In parallel, Dr. Ruhinda will assist in identifying\nand evaluating clinical sites suitable for a pilot program to demonstrate\nproof of concept.\n\nXcelerate provided funding for the consulting services under the agreement.\n\nSeparately, the Company confirmed that its Chief Science Officer, Dr. Anja\nGlisovic, will be on-site in May to lead research and development discussions,\nadvance intellectual property strategies, and support the evaluation of\nhigh-growth medical technology opportunities.\n\nDr. Glisovic has served as Chief Science Officer of Xcelerate and brings\nextensive experience in advanced scientific research, product development, and\ninnovation leadership. She received her PhD in X-Ray and Material Physics from\nGermany's Georg-August Universität and has held senior roles, including Head\nof R&D Laboratory and R&D Project Leader at the Fraunhofer Institute, a\nglobally recognized applied research organization. She holds multiple patents\nacross medical devices, chemical engineering, and related technologies. Her\nupcoming visit is expected to further align the Company's R&D initiatives with\nits broader strategy of building a differentiated portfolio of medical\ntechnologies and intellectual property assets.\n\nMichael O'Shea, Chief Executive Officer of Xcelerate, commented: \"In our\nrecent strategic update, we identified 2026 as a year focused on execution.\nEngaging Dr. Ruhinda allows us to begin the critical groundwork required to\nevaluate how advanced healthcare technologies, such as AdviNOW, can be adapted\nfor the Tanzanian healthcare environment. His regional expertise will be key\nas we assess localization requirements and prepare for a potential pilot\nclinic program.\n\nWe are also pleased that our Chief Science Officer, Dr. Glisovic, will be\non-site in May. Her leadership in research and development and intellectual\nproperty strategy is central to advancing our technology roadmap and\nidentifying new opportunities within the medical sector.\"\n\nDr. Ruhinda is a Tanzanian medical doctor and healthcare professional with\nextensive experience in clinical care, healthcare systems, and medical program\ndevelopment. He is a Bertha Scholar at the University of Cape Town and a Young\nAfrican Leaders Initiative (YALI) Fellow. Previously, he co-founded and helped\nscale a hybrid healthcare delivery model in Tanzania, leading clinical and\noperational teams that supported over 15,000 patients through integrated\nservices, including diagnostics, pharmacy, and telemedicine. His work focuses\non strengthening healthcare systems by translating AI capabilities into\npractical, scalable solutions that improve access, coordination, and patient\noutcomes.\n\nManagement believes the completion of this evaluation phase will provide\nimportant insight into the feasibility, cost structure, and operational\nframework required for introducing AI-supported healthcare systems in emerging\nmarkets.\n\nABOUT XCELERATE INC.\n\nIn May 2020, Xcelerate commenced implementation of a new business plan that\nencompasses two separate but related businesses within the medical industry,\nincluding (i) owning and licensing the rights to various forms of medical\nequipment and portfolio of patents, patents pending and technology licenses;\nand (ii) development of virtual health technology to assist patients in\ndeveloping countries obtain medical care by extending the reach of physicians\nthrough the use of that technology.\n\nFor more information\n\nvisit www.xcelerate.global or contact us at 854-900-2020 or email\ninfo@xcelerate.global.\n\nSAFE HARBOR\n\nThis press release may contain forward-looking information within the meaning\nof Section 21E of the Securities Exchange Act of 1934, as amended (the\n\"Exchange Act\"), including all statements that are not statements of\nhistorical fact regarding the intent, belief or current expectations of the\nCompany, its directors or its officers with respect to, among other things:\n(i) the Company's financing plans; (ii) trends affecting the Company's\nfinancial condition or results of operations; (iii) the Company's growth\nstrategy and operating strategy; and (iv) the declaration and payment of\ndividends. The words \"may,\" \"would,\" \"will,\" \"expect,\" \"estimate,\"\n\"anticipate,\" \"believe,\" \"intend,\" and similar expressions and variations\nthereof are intended to identify forward-looking statements. Investors are\ncautioned any such forward-looking statements are not guarantees of future\nperformance and involve risks and uncertainties, many of which are beyond the\nCompany's ability to control, and actual results may differ materially from\nthose projected in forward-looking statements resulting from various factors.\n\nSOURCE: Xcelerate\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/xcelerate-announces-agreements-with-tanzanian-medical-professionals-1163428)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACS1597ha","title":"Xcelerate Announces Agreements with Tanzanian Medical Professionals","author":"ACCESSWIRE","ticker":"XCRT","created":"2026-05-04T13:24:44.133Z","tickers":["XCRT"],"exchange":"OTC","article_body":"XCELERATE ANNOUNCES AGREEMENTS WITH TANZANIAN MEDICAL PROFESSIONALS TO BEGIN\nLOCAL OPERATIONS\n\nAgreement with Dr. Desire Ruhinda will allow the Company to move forward with\nits pilot program\n\nMAULDIN, SC / ACCESS Newswire (https://www.accessnewswire.com/) / May 4, 2026\n/ Xcelerate Inc. (OTCQB:XCRT) today announced that its majority-owned\nsubsidiary, AfiyaSasa Africa LLC, has entered into a consulting agreement with\nTanzanian medical doctor Dr. Desire Ruhinda to support the next phase of the\nCompany's AfiyaSasa Africa initiative, while also confirming a May on-site R&D\nengagement led by its Chief Science Officer, Dr. Anja Glisovic.\n\nThe agreement with Dr. Ruhinda marks a transition from strategic planning to\noperational execution of the Company's previously announced initiative to\nevaluate artificial intelligence-enabled healthcare delivery models in\nunderserved markets.\n\nUnder the agreement, current efforts will focus on reviewing the capabilities\nof the AdviNOW Medical system, identifying localization requirements, and\ncompiling clinical data aligned with Tanzanian treatment guidelines and\npharmaceutical standards. In parallel, Dr. Ruhinda will assist in identifying\nand evaluating clinical sites suitable for a pilot program to demonstrate\nproof of concept.\n\nXcelerate provided funding for the consulting services under the agreement.\n\nSeparately, the Company confirmed that its Chief Science Officer, Dr. Anja\nGlisovic, will be on-site in May to lead research and development discussions,\nadvance intellectual property strategies, and support the evaluation of\nhigh-growth medical technology opportunities.\n\nDr. Glisovic has served as Chief Science Officer of Xcelerate and brings\nextensive experience in advanced scientific research, product development, and\ninnovation leadership. She received her PhD in X-Ray and Material Physics from\nGermany's Georg-August Universität and has held senior roles, including Head\nof R&D Laboratory and R&D Project Leader at the Fraunhofer Institute, a\nglobally recognized applied research organization. She holds multiple patents\nacross medical devices, chemical engineering, and related technologies. Her\nupcoming visit is expected to further align the Company's R&D initiatives with\nits broader strategy of building a differentiated portfolio of medical\ntechnologies and intellectual property assets.\n\nMichael O'Shea, Chief Executive Officer of Xcelerate, commented: \"In our\nrecent strategic update, we identified 2026 as a year focused on execution.\nEngaging Dr. Ruhinda allows us to begin the critical groundwork required to\nevaluate how advanced healthcare technologies, such as AdviNOW, can be adapted\nfor the Tanzanian healthcare environment. His regional expertise will be key\nas we assess localization requirements and prepare for a potential pilot\nclinic program.\n\nWe are also pleased that our Chief Science Officer, Dr. Glisovic, will be\non-site in May. Her leadership in research and development and intellectual\nproperty strategy is central to advancing our technology roadmap and\nidentifying new opportunities within the medical sector.\"\n\nDr. Ruhinda is a Tanzanian medical doctor and healthcare professional with\nextensive experience in clinical care, healthcare systems, and medical program\ndevelopment. He is a Bertha Scholar at the University of Cape Town and a Young\nAfrican Leaders Initiative (YALI) Fellow. Previously, he co-founded and helped\nscale a hybrid healthcare delivery model in Tanzania, leading clinical and\noperational teams that supported over 15,000 patients through integrated\nservices, including diagnostics, pharmacy, and telemedicine. His work focuses\non strengthening healthcare systems by translating AI capabilities into\npractical, scalable solutions that improve access, coordination, and patient\noutcomes.\n\nManagement believes the completion of this evaluation phase will provide\nimportant insight into the feasibility, cost structure, and operational\nframework required for introducing AI-supported healthcare systems in emerging\nmarkets.\n\nABOUT XCELERATE INC.\n\nIn May 2020, Xcelerate commenced implementation of a new business plan that\nencompasses two separate but related businesses within the medical industry,\nincluding (i) owning and licensing the rights to various forms of medical\nequipment and portfolio of patents, patents pending and technology licenses;\nand (ii) development of virtual health technology to assist patients in\ndeveloping countries obtain medical care by extending the reach of physicians\nthrough the use of that technology.\n\nFor more information\n\nvisit www.xcelerate.global or contact us at 854-900-2020 or email\ninfo@xcelerate.global.\n\nSAFE HARBOR\n\nThis press release may contain forward-looking information within the meaning\nof Section 21E of the Securities Exchange Act of 1934, as amended (the\n\"Exchange Act\"), including all statements that are not statements of\nhistorical fact regarding the intent, belief or current expectations of the\nCompany, its directors or its officers with respect to, among other things:\n(i) the Company's financing plans; (ii) trends affecting the Company's\nfinancial condition or results of operations; (iii) the Company's growth\nstrategy and operating strategy; and (iv) the declaration and payment of\ndividends. The words \"may,\" \"would,\" \"will,\" \"expect,\" \"estimate,\"\n\"anticipate,\" \"believe,\" \"intend,\" and similar expressions and variations\nthereof are intended to identify forward-looking statements. Investors are\ncautioned any such forward-looking statements are not guarantees of future\nperformance and involve risks and uncertainties, many of which are beyond the\nCompany's ability to control, and actual results may differ materially from\nthose projected in forward-looking statements resulting from various factors.\n\nSOURCE: Xcelerate\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/xcelerate-announces-agreements-with-tanzanian-medical-professionals-1163428)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-04T13:24:44.197826615Z","server_sent_at_ms":1777901084197},"received_at":"2026-05-04T13:24:44.259Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/xcelerate-announces-agreements-with-tanzanian-medical-professionals-1163428"},"analysis":null,"durationMs":null,"modelName":null}}